Affinity Asset Advisors’s Cogent Biosciences COGT Stock Holding History

Affinity Asset Advisors’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.9M	Buy	750,000 +400,000	+114%	+$14.8M	1.49%	21
2025 Q4	$12.4M	Buy	+350,000	New	+$9.84M	0.71%	40
2023 Q2	–	Sell	-143,064	Closed	-$1.54M	–	75
2023 Q1	$1.54M	Sell	143,064 -50,000	-26%	-$640K	0.51%	48
2022 Q4	$2.23M	Buy	193,064 +38,977	+25%	+$483K	0.88%	36
2022 Q3	$2.3M	Buy	154,087 +29,087	+23%	+$399K	0.64%	35
2022 Q2	$1.13M	Buy	+125,000	New	+$853K	0.48%	39

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Affinity Asset Advisors's COGT Position: Q1 2026 in Review

Affinity Asset Advisors increased its Cogent Biosciences (COGT) stake by 114% in Q1 2026, buying an estimated $14.8M and bringing the position to 750,000 shares worth $28.9M. The position accounts for 1.49% of the portfolio, ranked #21.

Affinity Asset Advisors first reported a position in COGT in Q2 2022 and has held it in 6 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

Affinity Asset Advisors held 750,000 shares of Cogent Biosciences worth $28.9M as of Q1 2026.
Affinity Asset Advisors bought 400,000 Cogent Biosciences shares in Q1 2026, an estimated $14.8M.
Cogent Biosciences made up 1.49% of Affinity Asset Advisors's portfolio in Q1 2026, its #21 holding.
Affinity Asset Advisors first reported a position in Cogent Biosciences in Q2 2022 and has held it in 6 quarters since.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.